These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 6382162)

  • 1. Heparin induced bleeding.
    Hirsh J
    Nouv Rev Fr Hematol (1978); 1984; 26(4):261-6. PubMed ID: 6382162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low molecular weight heparins].
    Kher A; Bara L; Samama M
    Pathol Biol (Paris); 1986 Jan; 34(1):61-9. PubMed ID: 3517772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of heparin fractions: issues and answers.
    Messmore HL
    Crit Rev Clin Lab Sci; 1986; 23(2):77-94. PubMed ID: 2419035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of low molecular weight heparins and heparinoids.
    Levine MN; Hirsh J
    Semin Thromb Hemost; 1988 Jan; 14(1):116-25. PubMed ID: 2451292
    [No Abstract]   [Full Text] [Related]  

  • 6. Heparin and its biocompatibility.
    Stiekema JC
    Clin Nephrol; 1986; 26 Suppl 1():S3-8. PubMed ID: 2435441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparin: a critical analysis of clinical trials.
    Green D; Hirsh J; Heit J; Prins M; Davidson B; Lensing AW
    Pharmacol Rev; 1994 Mar; 46(1):89-109. PubMed ID: 8190751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin: from the bench to the orthopedic patient.
    Turpie AG
    Orthopedics; 1997 Feb; 20 Suppl():10-3. PubMed ID: 9048401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
    Hull RD; Pineo GF; Stein P
    Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successors to heparin: new antithrombotic agents.
    Turpie AG
    Am Heart J; 1997 Nov; 134(5 Pt 2):S71-7. PubMed ID: 9396637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Heparin during acute ischemic stroke. Present data and clinical situation].
    Daffertshofer M; Grips E; Dempfle CE; Hennerici M
    Nervenarzt; 2003 Apr; 74(4):307-19. PubMed ID: 12707700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y; Hosaka Y; Imada K; Adachi T; Niina H; Watanabe M; Mochizuki H
    Thromb Haemost; 1997 Apr; 77(4):789-95. PubMed ID: 9134660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [-Anticoagulant drugs-].
    Gulba DC
    Herz; 1996 Feb; 21(1):12-27. PubMed ID: 8647576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
    Davidson BL; Büller HR; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob GE; Segers AE; Lensing AW;
    J Thromb Haemost; 2007 Jun; 5(6):1191-4. PubMed ID: 17403087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
    Farias WR; Nazareth RA; Mourão PA
    Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [From heparin to synthetic antithrombotic drugs].
    Palareti G; Cosmi B
    Minerva Anestesiol; 2001 Sep; 67(9 Suppl 1):76-81. PubMed ID: 11778099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of established antithrombotic strategies.
    Haas S
    Blood Coagul Fibrinolysis; 1999 Aug; 10 Suppl 2():S11-8. PubMed ID: 10493226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.